Chronic kidney disease, commonly referred to as CKD, affects millions of people worldwide and is widely recognized for its impact on cardiovascular health, metabolism, and overall mortality. What receives far less attention is how CKD influences the gastrointestinal system, particularly gastric motility. Emerging research now suggests that gastroparesis, a disorder characterized by delayed stomach emptying, may represent a hidden yet clinically meaningful burden among patients with CKD.
A recent large-scale study published in the Journal of Personalized Medicine provides compelling evidence that gastroparesis occurs more frequently in individuals with CKD than in the general population. By analyzing both inpatient and outpatient datasets across the United States, the authors demonstrate that the likelihood of gastroparesis increases as kidney function declines, with the highest risk observed in patients with end-stage renal disease. These findings have important implications for early detection, symptom management, and personalized care strategies in nephrology.
Gastroparesis is a chronic condition in which the stomach empties food into the small intestine more slowly than normal, without the presence of a physical blockage. Symptoms commonly include nausea, vomiting, early satiety, bloating, abdominal discomfort, and poor appetite. Over time, these symptoms can lead to malnutrition, dehydration, electrolyte disturbances, and reduced quality of life.
Diagnosis typically involves ruling out mechanical obstruction through imaging or endoscopy, followed by confirmation with gastric emptying studies such as scintigraphy. Despite standardized diagnostic criteria, gastroparesis is often underdiagnosed because its symptoms overlap with more common disorders such as functional dyspepsia or gastroesophageal reflux disease.
Patients with CKD frequently report upper gastrointestinal complaints, especially in advanced stages of disease. Nausea, vomiting, and poor appetite are often attributed to uremia, fluid shifts, or medication side effects. As a result, underlying motility disorders like gastroparesis may go unrecognized.
Survey data indicate that up to 70 percent of individuals with CKD experience symptoms suggestive of gastric dysmotility. However, only a small proportion undergo formal evaluation for delayed gastric emptying. This diagnostic gap may contribute to preventable complications such as recurrent dehydration, malnutrition, and accelerated loss of residual kidney function.
The MDPI study analyzed two large datasets to address this knowledge gap. The National Inpatient Sample database included more than seven million hospitalized patients, while the TriNetX database provided longitudinal outpatient data from ambulatory clinics.
Across both datasets, CKD was consistently associated with higher odds of gastroparesis. In the inpatient cohort, patients with CKD were more than four times as likely to have a diagnosis of gastroparesis compared with those without kidney disease. The risk increased progressively with CKD severity, reaching its peak among patients with end-stage renal disease.
In the outpatient cohort, similar trends were observed even after rigorous propensity score matching to control for confounding factors such as age, diabetes, hypertension, smoking, and medication use. Patients with CKD had more than double the risk of gastroparesis, and those receiving dialysis were at even higher risk.
These findings suggest that CKD itself may be an independent risk factor for gastroparesis rather than merely a marker of shared comorbidities.
Diabetes is a well-established cause of gastroparesis and is also the leading cause of CKD. This overlap has historically made it difficult to determine whether kidney disease independently contributes to gastric dysmotility. Importantly, the study found that the association between CKD and gastroparesis persisted even after adjusting for diabetes and excluding patients with uncontrolled disease.
This observation supports the hypothesis that mechanisms intrinsic to CKD may directly impair gastrointestinal motility. Advanced kidney disease is associated with autonomic nervous system dysfunction, accumulation of uremic toxins, chronic inflammation, and oxidative stress. Each of these factors has the potential to disrupt normal gastric emptying.
Several biological pathways may explain the link between CKD and gastroparesis. Reduced clearance of uremic toxins in advanced CKD can impair autonomic nerve signaling, leading to abnormal gastric and intestinal motility. Studies have also demonstrated alterations in the migrating motor complex, which plays a critical role in coordinating digestive activity between meals.
Another proposed mechanism involves nitric oxide deficiency. Nitric oxide is essential for smooth muscle relaxation in the gastrointestinal tract. Patients with CKD have been shown to exhibit reduced nitric oxide production, partly due to elevated levels of asymmetric dimethylarginine, an inhibitor of nitric oxide synthase. Experimental and clinical studies suggest that diminished nitric oxide signaling may contribute to delayed gastric emptying.
Additionally, impaired motility may promote small intestinal bacterial overgrowth, further exacerbating gastrointestinal symptoms and increasing the burden of uremic toxins. This creates a self-reinforcing cycle that worsens both digestive and renal outcomes.
The recognition of gastroparesis as a common yet underappreciated comorbidity in CKD has important clinical implications. Early identification of gastric motility disorders may help clinicians address symptoms before they lead to serious complications.
For patients with advanced CKD who report persistent nausea, early satiety, or postprandial discomfort, referral for gastroenterologic evaluation may be warranted. Dietary modification, optimization of hydration, and targeted pharmacologic therapy could improve nutritional status and quality of life. In some cases, symptom control may also reduce hospitalizations related to dehydration or electrolyte imbalance.
From a personalized medicine perspective, integrating gastrointestinal symptom assessment into routine CKD care may allow for more individualized treatment strategies. This approach aligns with growing emphasis on multidisciplinary management for complex chronic diseases.
While the study provides robust evidence from large datasets, it is not without limitations. Diagnoses were based on ICD coding rather than standardized gastric emptying tests, and temporal relationships could not be fully established. Longitudinal studies with direct physiological measurements are needed to confirm causality and clarify disease progression.
Future research may also explore whether interventions such as dialysis initiation, modulation of gut microbiota, or therapies targeting autonomic dysfunction can improve gastric motility in CKD patients. Prospective trials could help establish screening recommendations and inform clinical guidelines.
Gastroparesis appears to be a significant yet frequently overlooked complication of chronic kidney disease, particularly in its advanced stages. Evidence from large inpatient and outpatient populations suggests that declining kidney function is associated with a substantially increased risk of delayed gastric emptying, independent of diabetes and other shared risk factors.
Recognizing this connection offers an opportunity to improve patient outcomes through earlier diagnosis, symptom management, and personalized care strategies. As awareness grows, addressing gastrointestinal health may become an integral component of comprehensive CKD management.
Wang X, Almetwali O, Marino-Melendez A, Tan D, Wang J, Song G. The Hidden Burden of Gastroparesis in Chronic Kidney Disease: Evidence from Inpatient and Outpatient Cohorts for Personalized Care. Journal of Personalized Medicine. 2025;15(12):600. https://doi.org/10.3390/jpm15120600
This blog article is intended for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Readers should consult qualified healthcare professionals regarding individual medical conditions or treatment decisions. The interpretations presented here are based on published research and do not necessarily reflect the views of the original authors or publishers.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.